Literature DB >> 15917160

Oestrogen regulated gene expression in normal and malignant endometrial tissue.

Sharon A O'Toole1, Elizabeth Dunn, Brian L Sheppard, Orla Sheils, John J O'Leary, Wolfgang Wuttke, Dana Seidlova-Wuttke.   

Abstract

OBJECTIVES: The aim of this study was to examine the expression of oestrogen regulated genes in premenopausal and postmenopausal normal and malignant endometrial specimens. The molecular mechanisms and the role of these genes in endometrial carcinogenesis are poorly understood.
METHODS: Normal and malignant endometrial specimens were collected from patients undergoing hysterectomy. Real time TaqMan PCR was used to examine the mRNA expression levels of oestrogen receptor a (ERa) and b (ERb), progesterone receptor (PR), insulin like growth factor 1 (IGF-1) and vascular endothelial growth factor (VEGF).
RESULTS: Expression analysis was carried out on 60 patients. ERa was more predominantly expressed in the endometrial samples than ERb, 28% of the specimens did not express ER. Normal pre and postmenopausal tissue expressed higher levels of ERa, PR and IGF-1 than malignant tissue. ERa and PR expression was significantly higher in the proliferative phase endometrium compared to the secretory phase (P < 0.05). PR mRNA expression was significantly correlated with ERa in all tissue types.
CONCLUSIONS: ERa expression may play an important role in the regulation of PR in normal and malignant endometrium. Further work is needed to establish if IGF-1 plays a role in a subset of endometrial cancers and if isoforms of VEGF play a role in endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917160     DOI: 10.1016/j.maturitas.2004.07.009

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  6 in total

1.  A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer.

Authors:  Marc J Gunter; Donald R Hoover; Herbert Yu; Sylvia Wassertheil-Smoller; Joann E Manson; Jixin Li; Tiffany G Harris; Thomas E Rohan; Xiaonan Xue; Gloria Y F Ho; Mark H Einstein; Robert C Kaplan; Robert D Burk; Judith Wylie-Rosett; Michael N Pollak; Garnet Anderson; Barbara V Howard; Howard D Strickler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04       Impact factor: 4.254

2.  Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).

Authors:  Mei Hong Zhang; Hong Tao Man; Xiao Dan Zhao; Ni Dong; Shi Liang Ma
Journal:  Biomed Rep       Date:  2013-10-25

3.  Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum.

Authors:  Matthew P Schlumbrecht; Su-Su Xie; Gregory L Shipley; Diana L Urbauer; Russell R Broaddus
Journal:  Mod Pathol       Date:  2010-11-19       Impact factor: 7.842

4.  Individual transcriptional activity of estrogen receptors in primary breast cancer and its clinical significance.

Authors:  Tatsuyuki Gohno; Yuko Seino; Toru Hanamura; Toshifumi Niwa; Mitsuyo Matsumoto; Nobuo Yaegashi; Hanako Oba; Masafumi Kurosumi; Hiroyuki Takei; Yuri Yamaguchi; Shin-Ichi Hayashi
Journal:  Cancer Med       Date:  2012-10-30       Impact factor: 4.452

5.  Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors.

Authors:  Melissa A Merritt; Howard D Strickler; Mark H Einstein; Hannah P Yang; Mark E Sherman; Nicolas Wentzensen; Jurriaan Brouwer-Visser; Maria Jose Cossio; Kathleen D Whitney; Herbert Yu; Marc J Gunter; Gloria S Huang
Journal:  Cancer Causes Control       Date:  2016-04-28       Impact factor: 2.506

6.  Immunohistochemical expression of insulin-like growth factor-1Ec in primary endometrial carcinoma: Association with PTEN, p53 and survivin expression.

Authors:  Aggelis Stavropoulos; Michail Varras; Anastassios Philippou; Thivi Vasilakaki; Viktoria-Konstantina Varra; Fani-Niki Varra; Aikaterini Tsavari; Andreas C Lazaris; Michael Koutsilieris
Journal:  Oncol Lett       Date:  2020-10-29       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.